• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting.

作者信息

Neumann F J, Gawaz M, Ott I, May A, Mössmer G, Schömig A

机构信息

Medizinische Klinik, Technischen Universität München, Germany.

出版信息

J Am Coll Cardiol. 1996 Jan;27(1):15-21. doi: 10.1016/0735-1097(95)00433-5.

DOI:10.1016/0735-1097(95)00433-5
PMID:8522689
Abstract

OBJECTIVES

This study sought to investigate hemostatic predictors of subacute occlusive coronary stent thrombosis.

BACKGROUND

Better hemostatic monitoring may improve antithrombotic therapy after stenting.

METHODS

In 140 consecutive patients undergoing Palmaz-Schatz stent implantation for suboptimal angioplasty results, we obtained serial blood samples immediately before and daily for 12 days after stenting. We prospectively tested the hypothesis that subacute stent thrombosis was more frequent if the surface expression of the inducible fibrinogen receptor on platelets (flow cytometry) or the concentration of plasma fibrinogen or that of the prothrombin fragments F1 + 2 before stent implantation exceeded the 75th percentile of the entire study cohort.

RESULTS

All five stent occlusions encountered during the study occurred in patients with platelet fibrinogen receptor expression above the 75th percentile. Thus, the rate of stent occlusion differed significantly between the groups defined by platelet fibrinogen receptor expression (14.3% vs. 0%, p = 0.0008). In both the group with fibrinogen concentration and that with F1 + 2 concentration above the 75th percentile, three stent occlusions occurred. Between the groups defined by these variables, the rate of stent occlusion did not differ significantly (8.6% vs. 1.9%, p = 0.10). Logistic regression analysis, including angiographic and hemostatic variables, confirmed platelet fibrinogen receptor expression as an independent predictor of stent occlusion (p = 0.020). Stent occlusion could not be predicted by the time course of any of the hemostatic variables.

CONCLUSIONS

Platelet fibrinogen receptor expression is an independent predictor of subacute stent occlusion. However, fibrinogen and F1 + 2 concentrations do not show a strong relation to the risk of stent occlusion.

摘要

相似文献

1
Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting.
J Am Coll Cardiol. 1996 Jan;27(1):15-21. doi: 10.1016/0735-1097(95)00433-5.
2
Role of activation-dependent platelet membrane glycoproteins in development of subacute occlusive coronary stent thrombosis.激活依赖性血小板膜糖蛋白在亚急性闭塞性冠状动脉支架血栓形成中的作用。
Coron Artery Dis. 1997 Mar-Apr;8(3-4):121-8. doi: 10.1097/00019501-199703000-00001.
3
Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis events.急性和亚急性支架血栓形成的临床、操作及药理学相关因素:一项包含145例血栓形成事件的多中心病例对照研究结果
Am Heart J. 2008 Apr;155(4):654-60. doi: 10.1016/j.ahj.2007.11.028. Epub 2008 Feb 21.
4
Platelet activation after stenting with heparin-coated versus noncoated stents.肝素涂层支架与非涂层支架置入术后的血小板活化
Am Heart J. 2003 Oct;146(4):E10. doi: 10.1016/S0002-8703(03)00317-X.
5
Does platelet glycoprotein IIb/IIIa receptor antibody improve in-hospital outcome of coronary stenting in high-risk thrombus containing lesions?血小板糖蛋白IIb/IIIa受体抗体能否改善高风险含血栓病变冠状动脉支架置入术的院内结局?
Catheter Cardiovasc Interv. 1999 Apr;46(4):415-20. doi: 10.1002/(SICI)1522-726X(199904)46:4<415::AID-CCD5>3.0.CO;2-Y.
6
Subacute occlusion, bleeding complications, hospital stay and restenosis after Palmaz-Schatz coronary stenting under a new antithrombotic regimen.
J Am Coll Cardiol. 1996 Jan;27(1):22-9. doi: 10.1016/0735-1097(95)00440-8.
7
Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation.与噻氯匹定相比,冠状动脉支架植入术后服用氯吡格雷的患者长期支架内血栓形成率和死亡率增加。
Int J Cardiol. 2005 Sep 1;103(3):293-7. doi: 10.1016/j.ijcard.2004.08.061.
8
Transradial Palmaz-Schatz coronary stenting on an outpatient basis: results of a prospective pilot study.
J Invasive Cardiol. 1995;7 Suppl A:5A-11A.
9
[Influence of various antithrombotic therapy methods on the incidence of subacute coronary stent occlusions, hemorrhagic complications and length of hospitalization].[各种抗血栓治疗方法对亚急性冠状动脉支架闭塞发生率、出血并发症及住院时间的影响]
Schweiz Med Wochenschr. 1998 Jan 17;128(3):72-9.
10
[Wiktor coronary stent for elective placement with an antiaggregation regimen. WINE study. WINE Group Study].
Rev Esp Cardiol. 1998 Jun;51(6):450-7.

引用本文的文献

1
Antiplatelet therapy for tibial balloon angioplasty: A clinical perspective.胫骨球囊血管成形术的抗血小板治疗:临床视角
SAGE Open Med. 2019 May 31;7:2050312119854579. doi: 10.1177/2050312119854579. eCollection 2019.
2
Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE).评估临床危险因素以预测稳定型冠状动脉疾病患者治疗期间的高血小板反应性及预后(PREDICT-STABLE研究)
PLoS One. 2015 Mar 23;10(3):e0121620. doi: 10.1371/journal.pone.0121620. eCollection 2015.
3
[Clinical pharmacology of current antiplatelet drugs].
[当前抗血小板药物的临床药理学]
Herz. 2014 Nov;39(7):790-7. doi: 10.1007/s00059-014-4151-9.
4
Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register.替罗非班辅助的直接经皮冠状动脉介入治疗在接受600mg氯吡格雷预处理患者中的疗效与安全性:使用塞尔维亚STEMI注册临床中心进行倾向分析的结果
Eur Heart J Acute Cardiovasc Care. 2014 Mar;3(1):56-66. doi: 10.1177/2048872613514013. Epub 2013 Nov 21.
5
Genetics of platelet inhibitor treatment.血小板抑制剂治疗的遗传学
Br J Clin Pharmacol. 2014 Apr;77(4):642-53. doi: 10.1111/bcp.12230.
6
Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel.改善接受经皮冠状动脉介入治疗患者的预后:普拉格雷的作用。
Vasc Health Risk Manag. 2009;5(1):475-81. doi: 10.2147/vhrm.s3969.
7
Coronary artery disease: Platelet activity: an obstacle for successful PCI.冠状动脉疾病:血小板活性:成功进行经皮冠状动脉介入治疗的一个障碍。
Nat Rev Cardiol. 2009 Jun;6(6):391-2. doi: 10.1038/nrcardio.2009.76.
8
The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention.急性冠状动脉综合征及经皮冠状动脉介入治疗后持续性血小板活化的问题。
Clin Cardiol. 2008 Mar;31(3 Suppl 1):I17-20. doi: 10.1002/clc.20363.
9
Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass.与传统非体外循环冠状动脉搭桥术相比,同期杂交冠状动脉血运重建术可降低术后发病率。
J Thorac Cardiovasc Surg. 2008 Feb;135(2):367-75. doi: 10.1016/j.jtcvs.2007.09.025. Epub 2007 Dec 26.
10
Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention.择期经皮冠状动脉介入治疗中的抗血小板和抗凝治疗。
Curr Control Trials Cardiovasc Med. 2001;2(3):129-140. doi: 10.1186/cvm-2-3-129.